Top

Published in:

01-09-2012 | Letter to the Editor

The evolution of personalized cancer genetic counseling in the era of personalized medicine

Authors: Hetal S. Vig, Catharine Wang

Published in: Familial Cancer | Issue 3/2012

Abstract

Practice changes in cancer genetic counseling have occurred to meet the demand for cancer genetic services. As cancer genetics continues to impact not only prevention strategies but also treatment decisions, current cancer genetic counseling models will need to be tailored to accommodate emerging clinical indications. These clinical indications include: surgical prophylactic bilateral mastectomy candidates, PARP-inhibitor candidates, patients with abnormal tumor screening results for Lynch syndrome, and post-test counseling patients (after genetic testing is ordered by another healthcare provider). A more personalized, multidisciplinary approach to selecting the best framework, for a given clinical indication, may become increasingly necessary in this era of personalized medicine.

Berliner JL, Fay AM (2007) Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 16(3):241–260PubMedCrossRef

Trepanier AM (2008) 2007 National Society of Genetic Counselors presidential address: embracing change to race forward. J Genet Couns 17(1):2–5PubMedCrossRef

Cavalli P (2009) Genetic counseling: a medical approach. Genet Test

Wham D, Vu T, Chan-Smutko G, Kobelka C, Urbauer D, Heald B (2010) Assessment of clinical practices among cancer genetic counselors. Fam Cancer 9(3):459–468PubMedCrossRef

Balint J, Shelton W (1996) Regaining the initiative. Forging a new model of the patient-physician relationship. JAMA 275(11):887–891PubMedCrossRef

Laine C, Davidoff F (1996) Patient-centered medicine. A professional evolution. JAMA 275(2):152–156PubMedCrossRef

Altman RB (2009) Direct-to-consumer genetic testing: failure is not an option. Clin Pharmacol Ther 86(1):15–17PubMedCrossRef

Plon SE, Cooper HP, Parks B et al (2011) Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 13(2):148–154PubMedCrossRef

Peshkin BN, Demarco TA, Graves KD et al (2008) Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test 12(1):37–52PubMedCrossRef

10.

Abrams DJ, Geier MR (2006) A comparison of patient satisfaction with telehealth and on-site consultations: a pilot study for prenatal genetic counseling. J Genet Couns 15(3):199–205PubMedCrossRef

11.

Helmes AW, Culver JO, Bowen DJ (2006) Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns 64(1–3):96–103PubMedCrossRef

12.

Sutphen R, Davila B, Shappell H et al (2010) Real world experience with cancer genetic counseling via telephone. Fam Cancer 9(4):681–689PubMedCrossRef

13.

Mackay J, Taylor A (2006) Moving genetics into clinical cancer care: examples from BRCA gene testing and telemedicine. Breast 15(Suppl 2):S65–S70PubMedCrossRef

14.

Meropol NJ, Daly MB, Vig HS et al (2011) Delivery of Internet-based cancer genetic counselling services to patients’ homes: a feasibility study. J Telemed Telecare 17(1):36–40

15.

Gray J, Brain K, Iredale R, Alderman J, France E, Hughes H (2000) A pilot study of telegenetics. J Telemed Telecare 6(4):245–247PubMedCrossRef

16.

Coelho JJ, Arnold A, Nayler J, Tischkowitz M, MacKay J (2005) An assessment of the efficacy of cancer genetic counselling using real-time videoconferencing technology (telemedicine) compared to face-to-face consultations. Eur J Cancer 41(15):2257–2261PubMedCrossRef

17.

Zon RT, Goss E, Vogel VG et al (2009) American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 27(6):986–993PubMedCrossRef

18.

Evans JP, Dale DC, Fomous C (2010) Preparing for a consumer-driven genomic age. N Engl J Med 363(12):1099–1103PubMedCrossRef

19.

Meiser B, Tucker K, Friedlander M et al (2008) Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res 10(6):216PubMedCrossRef

20.

Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823–1829PubMedCrossRef

21.

Patenaude AF, Orozco S, Li X et al (2008) Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psychooncology 17(8):831–843PubMedCrossRef

22.

Julian-Reynier C, Bouhnik AD, Mouret-Fourme E et al (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med 12(12):801–807PubMedCrossRef

23.

Silva E (2008) Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist. Fam Cancer 7(1):91–95PubMedCrossRef

24.

Silva E, Lynch H (2006) Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations. Breast J 12(3):280–281 (author reply 2–4)

25.

Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW (2004) Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Breast J 10(6):475–80

26.

American Society of Clinical Oncology policy statement update (2003) Genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397–2406CrossRef

27.

ACOG Practice Bulletin No (2009) 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957–966

28.

Wevers MR, Ausems MG, Verhoef S et al (2011) Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer 11:6PubMedCrossRef

29.

O’Connor AM, Stacey D, Rovner D et al (2001) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 3:CD001431

30.

Lobb EA, Butow PN, Moore A et al (2006) Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study. J Genet Couns 15(5):393–405PubMedCrossRef

31.

Wakefield CE, Meiser B, Homewood J et al (2008) A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology 17(8):844–854PubMedCrossRef

32.

Culver JO, Macdonald DJ, Thornton AA et al (2011) Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns 20(3):294–307PubMedCrossRef

33.

Amir E, Seruga B, Serrano R, Ocana A (2010) Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev 36(7):557–565PubMedCrossRef

34.

Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921PubMedCrossRef

35.

Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3):167–181PubMedCrossRef

36.

Bast RC Jr, Mills GB (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28(22):3545–3548PubMedCrossRef

37.

Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134PubMedCrossRef

38.

O’Shaughnessy J. SL, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer (TNBC). American Society of Clinical Oncology annual meeting, Chicago, IL

39.

Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082–1089PubMedCrossRef

40.

Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86PubMedCrossRef

41.

Hampel H, Frankel W, Panescu J et al (2006) Screening for lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817PubMedCrossRef

42.

Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788PubMedCrossRef

43.

Hampel H, Frankel WL, Martin E et al (2005) Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRef

44.

Recommendations from the EGAPP Working Group (2009) Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from lynch syndrome in relatives. Genet Med 11(1):35–41CrossRef

45.

South CD, Yearsley M, Martin E, Arnold M, Frankel W, Hampel H (2009) Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med 11(11):812–817PubMedCrossRef

46.

de la Chapelle A, Hampel H (2004) Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28(20):3380–3387

47.

Manne SL, Meropol NJ, Weinberg DS et al (2010) Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol 28(8):1366–1372

48.

Acheson LS, Stange KC, Zyzanski S (2005) Clinical genetics issues encountered by family physicians. Genet Med 7(7):501–508PubMedCrossRef

49.

Friedman LC, Cooper HP, Webb JA, Weinberg AD, Plon SE (2003) Primary care physicians’ attitudes and practices regarding cancer genetics: a comparison of 2001 with 1996 survey results. J Cancer Educ 18(2):91–4

50.

Wideroff L, Freedman AN, Olson L et al (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 12(4):295–303PubMed

51.

Cohen SA, McIlvried D, Schnieders J (2009) A collaborative approach to genetic testing: a community hospital’s experience. J Genet Couns 18(6):530–533PubMedCrossRef

52.

Vig HS, Armstrong J, Egleston BL et al (2009) Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 13(6):735–741PubMedCrossRef

Title: The evolution of personalized cancer genetic counseling in the era of personalized medicine
Authors: Hetal S. Vig
Catharine Wang
Publication date: 01-09-2012
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2012
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-012-9524-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations

Ameloblastoma: a neglected criterion for nevoid basal cell carcinoma (Gorlin) syndrome

The IL-10 promoter haplotype and cancer risk: evidence from a meta-analysis

Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance

Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women

Common MUTYH mutations and colorectal cancer risk in multiethnic populations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer